Powered by

Don't fret about Lilly's 3rd-to-market start in CGRP, executive says. It's got big plans in migraine and pain

Jan 09, 2019 - FiercePharma

SAN FRANCISCO—Eli Lilly's Emgality didn't take the first-to-market crown in the budding CGRP field of migraine prevention drugs. It didn't even come in second. But a top executive believes Lilly has what it takes to makeEmgality not only stand out from the crowd, but becomethe cornerstone of a migraine and pain franchise.

For one thing, the company has expertise in "consumer driven" fields like migraine,Lilly Bio-Medicines President Christi Shaw told FiercePharma, where patients tend to ...